vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Arhaus, Inc. (ARHS). Click either name above to swap in a different company.
Arhaus, Inc. is the larger business by last-quarter revenue ($364.8M vs $183.1M, roughly 2.0× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 4.1%, a 9.2% gap on every dollar of revenue. On growth, Arhaus, Inc. posted the faster year-over-year revenue change (5.1% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-8.8M). Over the past eight quarters, Arhaus, Inc.'s revenue compounded faster (11.2% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Arhaus, Inc.ARHSEarnings & Financial Report
Arhaus, Inc. is an upscale American home furnishings company headquartered in Boston Heights, Ohio. Founded in 1986 with a focus on sustainability and artisanship in product quality, Arhaus provides a diversified assortment of specialty goods and services addressing omnichannel direct-to-consumer and business-to-business residential and commercial operations.
AMPH vs ARHS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $364.8M |
| Net Profit | $24.4M | $15.1M |
| Gross Margin | 46.8% | 38.1% |
| Operating Margin | 19.4% | 5.6% |
| Net Margin | 13.3% | 4.1% |
| Revenue YoY | -1.8% | 5.1% |
| Net Profit YoY | -35.7% | -29.1% |
| EPS (diluted) | $0.51 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $364.8M | ||
| Q3 25 | $191.8M | $344.6M | ||
| Q2 25 | $174.4M | $358.4M | ||
| Q1 25 | $170.5M | $311.4M | ||
| Q4 24 | $186.5M | $347.0M | ||
| Q3 24 | $191.2M | $319.1M | ||
| Q2 24 | $182.4M | $309.8M | ||
| Q1 24 | $171.8M | $295.2M |
| Q4 25 | $24.4M | $15.1M | ||
| Q3 25 | $17.4M | $12.2M | ||
| Q2 25 | $31.0M | $35.1M | ||
| Q1 25 | $25.3M | $4.9M | ||
| Q4 24 | $38.0M | $21.3M | ||
| Q3 24 | $40.4M | $9.9M | ||
| Q2 24 | $37.9M | $22.2M | ||
| Q1 24 | $43.2M | $15.1M |
| Q4 25 | 46.8% | 38.1% | ||
| Q3 25 | 51.4% | 38.7% | ||
| Q2 25 | 49.6% | 41.4% | ||
| Q1 25 | 50.0% | 37.1% | ||
| Q4 24 | 46.5% | 40.0% | ||
| Q3 24 | 53.3% | 38.6% | ||
| Q2 24 | 52.2% | 40.1% | ||
| Q1 24 | 52.4% | 39.0% |
| Q4 25 | 19.4% | 5.6% | ||
| Q3 25 | 13.2% | 4.8% | ||
| Q2 25 | 24.2% | 13.0% | ||
| Q1 25 | 21.9% | 1.7% | ||
| Q4 24 | 24.2% | 8.2% | ||
| Q3 24 | 29.8% | 3.3% | ||
| Q2 24 | 30.3% | 9.5% | ||
| Q1 24 | 27.9% | 6.2% |
| Q4 25 | 13.3% | 4.1% | ||
| Q3 25 | 9.0% | 3.5% | ||
| Q2 25 | 17.8% | 9.8% | ||
| Q1 25 | 14.8% | 1.6% | ||
| Q4 24 | 20.4% | 6.1% | ||
| Q3 24 | 21.1% | 3.1% | ||
| Q2 24 | 20.8% | 7.2% | ||
| Q1 24 | 25.1% | 5.1% |
| Q4 25 | $0.51 | $0.11 | ||
| Q3 25 | $0.37 | $0.09 | ||
| Q2 25 | $0.64 | $0.25 | ||
| Q1 25 | $0.51 | $0.03 | ||
| Q4 24 | $0.74 | $0.15 | ||
| Q3 24 | $0.78 | $0.07 | ||
| Q2 24 | $0.73 | $0.16 | ||
| Q1 24 | $0.81 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $253.4M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $418.2M |
| Total Assets | $1.6B | $1.4B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $253.4M | ||
| Q3 25 | $276.2M | $262.2M | ||
| Q2 25 | $231.8M | $234.8M | ||
| Q1 25 | $236.9M | $214.4M | ||
| Q4 24 | $221.6M | $197.5M | ||
| Q3 24 | $250.5M | $177.7M | ||
| Q2 24 | $217.8M | $174.2M | ||
| Q1 24 | $289.6M | $233.2M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $418.2M | ||
| Q3 25 | $776.7M | $400.4M | ||
| Q2 25 | $757.5M | $385.6M | ||
| Q1 25 | $751.3M | $348.8M | ||
| Q4 24 | $732.3M | $343.7M | ||
| Q3 24 | $727.7M | $320.6M | ||
| Q2 24 | $713.3M | $309.3M | ||
| Q1 24 | $672.4M | $285.6M |
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.6B | $1.2B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $9.3M |
| Free Cash FlowOCF − Capex | $24.6M | $-8.8M |
| FCF MarginFCF / Revenue | 13.4% | -2.4% |
| Capex IntensityCapex / Revenue | 4.5% | 5.0% |
| Cash ConversionOCF / Net Profit | 1.35× | 0.62× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $59.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $9.3M | ||
| Q3 25 | $52.6M | $46.1M | ||
| Q2 25 | $35.6M | $34.9M | ||
| Q1 25 | $35.1M | $46.5M | ||
| Q4 24 | $29.0M | $31.7M | ||
| Q3 24 | $60.0M | $31.1M | ||
| Q2 24 | $69.1M | $47.5M | ||
| Q1 24 | $55.3M | $36.8M |
| Q4 25 | $24.6M | $-8.8M | ||
| Q3 25 | $47.2M | $28.0M | ||
| Q2 25 | $25.0M | $20.9M | ||
| Q1 25 | $24.4M | $18.9M | ||
| Q4 24 | $16.6M | $13.0M | ||
| Q3 24 | $46.2M | $4.6M | ||
| Q2 24 | $63.1M | $11.3M | ||
| Q1 24 | $46.5M | $10.9M |
| Q4 25 | 13.4% | -2.4% | ||
| Q3 25 | 24.6% | 8.1% | ||
| Q2 25 | 14.3% | 5.8% | ||
| Q1 25 | 14.3% | 6.1% | ||
| Q4 24 | 8.9% | 3.7% | ||
| Q3 24 | 24.1% | 1.4% | ||
| Q2 24 | 34.6% | 3.6% | ||
| Q1 24 | 27.1% | 3.7% |
| Q4 25 | 4.5% | 5.0% | ||
| Q3 25 | 2.8% | 5.3% | ||
| Q2 25 | 6.1% | 3.9% | ||
| Q1 25 | 6.3% | 8.9% | ||
| Q4 24 | 6.7% | 5.4% | ||
| Q3 24 | 7.2% | 8.3% | ||
| Q2 24 | 3.3% | 11.7% | ||
| Q1 24 | 5.1% | 8.8% |
| Q4 25 | 1.35× | 0.62× | ||
| Q3 25 | 3.03× | 3.77× | ||
| Q2 25 | 1.15× | 1.00× | ||
| Q1 25 | 1.39× | 9.53× | ||
| Q4 24 | 0.76× | 1.49× | ||
| Q3 24 | 1.48× | 3.14× | ||
| Q2 24 | 1.82× | 2.14× | ||
| Q1 24 | 1.28× | 2.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ARHS
| Sales Channel Retail | $305.7M | 84% |
| Sales Channel E Commerce | $59.2M | 16% |
